May 26, 2022

Neuvivo Closes on Additional Funding Round for NP001 Development

Palo Alto, CA, May 26, 2022: Neuvivo, a late-clinical stage biopharmaceutical company developing a new ALS treatment, today announced that it has closed on an additional round of financing led by an international investment group. The Bay Area-based company is currently in regulatory discussions with the FDA around its lead candidate, NP001, for ALS.

“We are pleased to have completed this next round of financing as we move ahead with development of a much needed, effective treatment for this devastating disease,” said Ari Azhir, PhD, Founder and CEO, Neuvivo.

About Neuvivo: Neuvivo is a private, late-clinical stage biopharmaceutical company committed to creating and delivering advanced treatments for ALS and other neurodegenerative diseases.  The company was formed by industry leaders and scientists, committed to improving the prognosis for patients diagnosed with ALS and a range of diseases for which few current treatment options exist.  For more information please visit: